Osteoarthritis and Cartilage
Volume 18, Issue 3 , Pages 279-288 , March 2010

MAPKs are essential upstream signaling pathways in proteolytic cartilage degradation – divergence in pathways leading to aggrecanase and MMP-mediated articular cartilage degradation

  • B.-C. Sondergaard

      Affiliations

    • Nordic Bioscience A/S, Herlev, Denmark
    • Corresponding Author InformationAddress correspondence and reprint requests to: Bodil-Cecilie Søndergaard, Nordic Bioscience, Herlev Hovedgade 207, DK-2730 Herlev, Denmark. Tel: 45-44-52-52-18; Fax: 45-44-52-52-51.
    • ,
  • N. Schultz

      Affiliations

    • Nordic Bioscience A/S, Herlev, Denmark
    • ,
  • S.H. Madsen

      Affiliations

    • Nordic Bioscience A/S, Herlev, Denmark
    • ,
  • A.-C. Bay-Jensen

      Affiliations

    • Nordic Bioscience A/S, Herlev, Denmark
    • ,
  • M. Kassem

      Affiliations

    • Department of Endocrinology, University of Southern Denmark, Odense, Denmark
    • ,
  • M.A. Karsdal

      Affiliations

    • Nordic Bioscience A/S, Herlev, Denmark

Received 4 June 2009 ,Accepted 4 November 2009.

References 

  1. Kiani C, Chen L, Wu YJ, Yee AJ, Yang BB. Structure and function of aggrecan. Cell Res. 2002 Mar;12(1):19–32
  2. Glasson SS, Askew R, Sheppard B, Carito B, Blanchet T, Ma HL, et al. Deletion of active ADAMTS5 prevents cartilage degradation in a murine model of osteoarthritis. Nature. 2005 Mar 31;434(7033):644–648
  3. Glasson SS, Askew R, Sheppard B, Carito BA, Blanchet T, Ma HL, et al. Characterization of and osteoarthritis susceptibility in ADAMTS-4-knockout mice. Arthritis Rheum. 2004 Aug;50(8):2547–2558
  4. East CJ, Stanton H, Golub SB, Rogerson FM, Fosang AJ. ADAMTS-5 deficiency does not block aggrecanolysis at preferred cleavage sites in the chondroitin sulfate-rich region of aggrecan. J Biol Chem. 2007 Mar 23;282(12):8632–8640
  5. Stanton H, Rogerson FM, East CJ, Golub SB, Lawlor KE, Meeker CT, et al. ADAMTS5 is the major aggrecanase in mouse cartilage in vivo and in vitro. Nature. 2005 Mar 31;434(7033):648–652
  6. Fosang AJ, Last K, Stanton H, Weeks DB, Campbell IK, Hardingham TE, et al. Generation and novel distribution of matrix metalloproteinase-derived aggrecan fragments in porcine cartilage explants. J Biol Chem. 2000 Oct 20;275(42):33027–33037
  7. Fosang AJ, Last K, Fujii Y, Seiki M, Okada Y. Membrane-type 1 MMP (MMP-14) cleaves at three sites in the aggrecan interglobular domain. FEBS Lett. 1998 Jul 3;430(3):186–190
  8. Fosang AJ, Last K, Maciewicz RA. Aggrecan is degraded by matrix metalloproteinases in human arthritis. Evidence that matrix metalloproteinase and aggrecanase activities can be independent. J Clin Invest. 1996 Nov 15;98(10):2292–2299
  9. Schaller S, Henriksen K, Hoegh-Andersen P, Sondergaard BC, Sumer EU, Tanko LB, et al. In vitro, ex vivo, and in vivo methodological approaches for studying therapeutic targets of osteoporosis and degenerative joint diseases: how biomarkers can assist?. Assay Drug Dev Technol. 2005 Oct;3(5):553–580
  10. Sondergaard BC, Henriksen K, Wulf H, Oestergaard S, Schurigt U, Brauer R, et al. Relative contribution of matrix metalloprotease and cysteine protease activities to cytokine-stimulated articular cartilage degradation. Osteoarthritis Cartilage. 2006 Aug;14(8):738–748
  11. Oestergaard S, Sondergaard BC, Hoegh-Andersen P, Henriksen K, Qvist P, Christiansen C, et al. Effects of ovariectomy and estrogen therapy on type II collagen degradation and structural integrity of articular cartilage in rats: implications of the time of initiation. Arthritis Rheum. 2006 Aug;54(8):2441–2451
  12. Billinghurst RC, Wu W, Ionescu M, Reiner A, Dahlberg L, Chen J, et al. Comparison of the degradation of type II collagen and proteoglycan in nasal and articular cartilages induced by interleukin-1 and the selective inhibition of type II collagen cleavage by collagenase. Arthritis Rheum. 2000 Mar;43(3):664–672
  13. Billinghurst RC, Dahlberg L, Ionescu M, Reiner A, Bourne R, Rorabeck C, et al. Enhanced cleavage of type II collagen by collagenases in osteoarthritic articular cartilage. J Clin Invest. 1997 Apr 1;99(7):1534–1545
  14. Fosang AJ, Neame PJ, Last K, Hardingham TE, Murphy G, Hamilton JA. The interglobular domain of cartilage aggrecan is cleaved by PUMP, gelatinases, and cathepsin B. J Biol Chem. 1992 Sep 25;267(27):19470–19474
  15. Sumer EU, Sondergaard BC, Rousseau JC, Delmas PD, Fosang AJ, Karsdal MA, et al. MMP and non-MMP-mediated release of aggrecan and its fragments from articular cartilage: a comparative study of three different aggrecan and glycosaminoglycan assays. Osteoarthritis Cartilage. 2007 Feb;15(2):212–221
  16. Karsdal MA, Sumer EU, Wulf H, Madsen SH, Christiansen C, Fosang AJ, et al. Induction of increased cAMP levels in articular chondrocytes blocks matrix metalloproteinase-mediated cartilage degradation, but not aggrecanase-mediated cartilage degradation. Arthritis Rheum. 2007 May;56(5):1549–1558
  17. Karsdal MA, Madsen SH, Christiansen C, Henriksen K, Fosang AJ, Sondergaard BC. Cartilage degradation is fully reversible in the presence of aggrecanase but not matrix metalloproteinase activity. Arthritis Res Ther. 2008;10(3):R63
  18. Abramson SB, Attur M, Yazici Y. Prospects for disease modification in osteoarthritis. Nat Clin Pract Rheumatol. 2006 Jun;2(6):304–312
  19. Pelletier JP, Martel-Pelletier J, Abramson SB. Osteoarthritis, an inflammatory disease: potential implication for the selection of new therapeutic targets. Arthritis Rheum. 2001 Jun;44(6):1237–1247
  20. Pelletier JP, Roughley PJ, DiBattista JA, McCollum R, Martel-Pelletier J. Are cytokines involved in osteoarthritic pathophysiology?. Semin Arthritis Rheum. 1991 Jun;20(6 Suppl 2):12–25
  21. Fernandes JC, Martel-Pelletier J, Pelletier JP. The role of cytokines in osteoarthritis pathophysiology. Biorheology. 2002;39(1–2):237–246
  22. Arend WP. Cytokine imbalance in the pathogenesis of rheumatoid arthritis: the role of interleukin-1 receptor antagonist. Semin Arthritis Rheum. 2001 Apr;30(5 Suppl 2):1–6
  23. Arend WP, Dayer JM. Cytokines and cytokine inhibitors or antagonists in rheumatoid arthritis. Arthritis Rheum. 1990 Mar;33(3):305–315
  24. Lawrence MC, Jivan A, Shao C, Duan L, Goad D, Zaganjor E, et al. The roles of MAPKs in disease. Cell Res. 2008 Apr;18(4):436–442
  25. Karsdal MA, Fjording MS, Foged NT, Delaisse JM, Lochter A. Transforming growth factor-beta-induced osteoblast elongation regulates osteoclastic bone resorption through a p38 mitogen-activated protein kinase- and matrix metalloproteinase-dependent pathway. J Biol Chem. 2001 Oct 19;276(42):39350–39358
  26. Bain J, Plater L, Elliott M, Shpiro N, Hastie CJ, McLauchlan H, et al. The selectivity of protein kinase inhibitors: a further update. Biochem J. 2007 Dec 15;408(3):297–315
  27. Ishikawa T, Nishigaki F, Christgau S, Noto T, Mo J, From N, et al. Cartilage destruction in collagen induced arthritis assessed with a new biochemical marker for collagen type II C-telopeptide fragments. J Rheumatol. 2004 Jun;31(6):1174–1179
  28. Karsdal MA, Leeming DJ, Dam EB, Henriksen K, Alexandersen P, Pastoureau P, et al. Should subchondral bone turnover be targeted when treating osteoarthritis?. Osteoarthritis Cartilage. 2008 Jun;16(6):638–646
  29. Zhen EY, Brittain IJ, Laska DA, Mitchell PG, Sumer EU, Karsdal MA, et al. Characterization of metalloprotease cleavage products of human articular cartilage. Arthritis Rheum. 2008 Aug;58(8):2420–2431
  30. Olsen AK, Sondergaard BC, Byrjalsen I, Tanko LB, Christiansen C, Muller A, et al. Anabolic and catabolic function of chondrocyte ex vivo is reflected by the metabolic processing of type II collagen. Osteoarthritis Cartilage. 2007 Mar;15(3):335–342
  31. Charni-Ben TN, Desmarais S, Bay-Jensen AC, Delaisse JM, Percival MD, Garnero P. The type II collagen fragments Helix-II and CTX-II reveal different enzymatic pathways of human cartilage collagen degradation. Osteoarthritis Cartilage. 2008 Oct;16(10):1183–1191
  32. Ridnour LA, Windhausen AN, Isenberg JS, Yeung N, Thomas DD, Vitek MP, et al. Nitric oxide regulates matrix metalloproteinase-9 activity by guanylyl-cyclase-dependent and -independent pathways. Proc Natl Acad Sci USA. 2007 Oct 23;104(43):16898–16903
  33. Tortorella MD, Liu RQ, Burn T, Newton RC, Arner E. Characterization of human aggrecanase 2 (ADAM-TS5): substrate specificity studies and comparison with aggrecanase 1 (ADAM-TS4). Matrix Biol. 2002 Oct;21(6):499–511
  34. Hui W, Rowan AD, Richards CD, Cawston TE. Oncostatin M in combination with tumor necrosis factor alpha induces cartilage damage and matrix metalloproteinase expression in vitro and in vivo. Arthritis Rheum. 2003 Dec;48(12):3404–3418
  35. Lochter A, Bissell MJ. An odyssey from breast to bone: multi-step control of mammary metastases and osteolysis by matrix metalloproteinases. APMIS. 1999 Jan;107:128–136
  36. Karsdal MA, Larsen L, Engsig MT, Lou H, Ferreras M, Lochter A, et al. Matrix metalloproteinase-dependent activation of latent transforming growth factor-beta controls the conversion of osteoblasts into osteocytes by blocking osteoblast apoptosis. J Biol Chem. 2002 Nov 15;277(46):44061–44067
  37. Liacini A, Sylvester J, Li WQ, Huang W, Dehnade F, Ahmad M, et al. Induction of matrix metalloproteinase-13 gene expression by TNF-alpha is mediated by MAP kinases, AP-1, and NF-kappaB transcription factors in articular chondrocytes. Exp Cell Res. 2003 Aug 1;288(1):208–217
  38. Yoon SW, Chun JS, Sung MH, Kim JY, Poo H. Alpha-MSH inhibits TNF-alpha-induced matrix metalloproteinase-13 expression by modulating p38 kinase and nuclear factor kappaB signaling in human chondrosarcoma HTB-94 cells. Osteoarthritis Cartilage. 2008 Jan;16(1):115–124
  39. Chen WD, Jiang Q, Chen DY, Xu H, Zhang YF. Effects of intra-articular injection of p38 mitogen-activated protein kinase inhibitor on matrix metalloproteinase in articular cartilage of a rat model of osteoarthritis. Zhongguo Yi Xue Ke Xue Yuan Xue Bao. 2007 Dec;29(6):777–781
  40. Ridley SH, Sarsfield SJ, Lee JC, Bigg HF, Cawston TE, Taylor DJ, et al. Actions of IL-1 are selectively controlled by p38 mitogen-activated protein kinase: regulation of prostaglandin H synthase-2, metalloproteinases, and IL-6 at different levels. J Immunol. 1997 Apr 1;158(7):3165–3173
  41. Mengshol JA, Vincenti MP, Coon CI, Barchowsky A, Brinckerhoff CE. Interleukin-1 induction of collagenase 3 (matrix metalloproteinase 13) gene expression in chondrocytes requires p38, c-Jun N-terminal kinase, and nuclear factor kappaB: differential regulation of collagenase 1 and collagenase 3. Arthritis Rheum. 2000 Apr;43(4):801–811
  42. El Mabrouk M, Sylvester J, Zafarullah M. Signaling pathways implicated in oncostatin M-induced aggrecanase-1 and matrix metalloproteinase-13 expression in human articular chondrocytes. Biochim Biophys Acta. 2007 Mar;1773(3):309–320
  43. Fan S, Meng Q, Laterra JJ, Rosen EM. Role of Src signal transduction pathways in scatter factor-mediated cellular protection. J Biol Chem. 2009 Mar 20;284(12):7561–7577
  44. Pechkovsky DV, Scaffidi AK, Hackett TL, Ballard J, Shaheen F, Thompson PJ, et al. Transforming growth factor beta1 induces alphavbeta3 integrin expression in human lung fibroblasts via a beta3 integrin-, c-Src-, and p38 MAPK-dependent pathway. J Biol Chem. 2008 May 9;283(19):12898–12908

PII: S1063-4584(09)00297-0

doi: 10.1016/j.joca.2009.11.005

Osteoarthritis and Cartilage
Volume 18, Issue 3 , Pages 279-288 , March 2010

Article Tools

* Image Usage & Resolution